FDA Approves Avapritinib for Rare Blood Disease

June 16, 2021

The FDA approved avapritinib (Ayvakit) for the treatment of adults with advanced systemic mastocytosis (AdvSM), including those with mast cell leukemia (MCL), aggressive systemic mastocytosism (ASM), or systemic mastocytosis with an associated hematological neoplasm (SM-AHN).

Discrepancies Exist Between Actual Care and Trial-Based Recommendations in MCL

June 14, 2021

A presentation at the European Hematology Association 2021 Virtual Congress demonstrated that discrepancies exist between actual patterns of care and recommendations based on clinical trials, according to a study of treatment patterns in adult patients with mantle cell lymphoma (MCL).

Age Associated With Survival, Time to Richter Transformation in AYA Patients With CLL

May 30, 2021

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.